Skip to Content

Press Releases

Press Releases

Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
Aug 17, 2022
Tiziana Life Sciences Announces Presentation at Alzheimer’s Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer’s Disease
Aug 01, 2022
Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer
Jul 18, 2022
Tiziana Life Sciences Announces Resignation of CEO
Jul 15, 2022
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
Jun 17, 2022
Tiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS Patient
Jun 09, 2022
Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient
Jun 09, 2022
Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient
Jun 09, 2022
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
Jun 09, 2022
Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab
Jun 08, 2022
Displaying 1 - 10 of 400